The prognosis for patients with respiratory syncytial virus (RSV) or parainfluenza virus type 3 (PIV3) respiratory tract infection post allogeneic haematopoietic progenitor cell transplant (HPCT) is historically poor. The use of oral ribavirin (RBV) has not been widely studied in this patient population. We examined the outcomes of 15 consecutive patients (RSV, n ¼ 13 and PIV3, n ¼ 2) treated with oral RBV post HPCT. Oral RBV was commenced at a starting dose of 10 mg/kg/day, increasing to a maximum dose of 60 mg/kg/day depending on response and tolerance. At diagnosis, seven patients had upper respiratory tract infection (URTI) and eight had lower respiratory tract infection (LRTI). The starting RBV dose of 10 mg/kg/day did not prevent the progression of URTI to LRTI in any patient. However, with dose escalation, six of the seven patients responded to RBV therapy and survived their infective episode. Of the eight patients presenting with LRTI, six patients survived their infection, again after dose escalation of RBV. There was no dose-limiting toxicity seen in any patient. Our results indicate that oral RBV has clinical efficacy in the treatment of RSV/PIV3 infection post HPCT. However, a starting dose of 10 mg/kg/day appears ineffective; we recommend a starting dose of 20 mg/kg/day in this patient group.
INTRODUCTION
The outcome of infection with respiratory syncytial virus (RSV) and parainfluenza 3 (PIV3) in allogeneic haematopoietic progenitor cell transplant (HPCT) patients is historically poor, with initial upper respiratory tract infection (URTI) often progressing to involvement of the lower respiratory tract (lower respiratory tract infection, LRTI) with development of pneumonitis and subsequent respiratory failure. [1] [2] [3] [4] Ribavirin (RBV) is a nucleoside analogue with broadspectrum antiviral activity against RNA viruses. 5 It is intercalated into the viral genome and enhances the mutation rate of the RNA virus, resulting in error catastrophe. 5 Several non-randomized studies have suggested the efficacy of RBV in the treatment of RSV and PIV3 infections in HPCT patients. However, the only randomised controlled trial of (aerosolised) RBV in this patient population closed prematurely because of slow patient accrual and thus was unable to prove or disprove the clinical efficacy of the drug. 6 RBV can be administered via nebulised, i.v. or oral routes. Nebulised RBV requires special environmental precautions that limit ease of delivery, and may also be associated with a variety of side effects, including cough, wheezing, breathlessness and deterioration in pulmonary function. 1, 7, 8 I.v. RBV is easier to administer, with the main associated toxicities being leukopenia and haemolytic anaemia. 8, 9 However, the need for eight-hourly dosing limits the application of i.v. RBV in an ambulatory care setting. Oral administration of RBV avoids all of the delivery issues associated with nebulised or i.v. RBV but is less well studied in HPCT patients.
Since 2009, our institution has used a standardised protocol incorporating oral RBV as therapy for symptomatic RSV and PIV3 infections in HPCT patients. Herein we report the outcome of patients treated with oral RBV at our institution; our experience not only supports the efficacy of oral RBV as treatment against RSV and PIV3 infection in HPCT patients but also highlights the benefits of antiviral therapy in an ambulatory care setting in this patient group.
MATERIALS AND METHODS
Outcomes of all HPCT patients treated with oral RBV for RSV and PIV3 respiratory infections were retrospectively reviewed. Patients were identified from a pharmacy database, and data with respect to infection manifestations and outcome were then collected from individual medical records.
All patients were treated on a standardised oral RBV protocol introduced at our institution in January 2009. Our protocol consisted of screening any post-HPCT patient with symptoms suggestive of viral infection with nasal pharyngeal aspirate (NPA) or nasopharyngeal swab. The samples were tested for respiratory viruses using qualitative multiplex PCR that had been developed within our institution (sensitivity 97% and 95% for RSV and PIV3, respectively). 10 Patients who tested positive for RSV or PIV3 were commenced on oral RBV at 10 mg/kg/day (total dose) given in four divided doses in combination with regular bronchodilators (nebulised salbutamol and ipratropium). Depending on clinical response and tolerance, oral RBV dose was escalated by 10 mg/kg/day every 24-48 h to a maximum of 60 mg/kg/day. Oral or i.v. methylprednisolone (starting dose 1 mg/kg/day) was also allowed in patients with significant bronchospasm/wheezing. Routine prophylactic i.v. Ig (IVIG; 0.4 g/kg weekly) was used in all HPCT patients at our institution until day 100 post HPCT and then monthly if persistently hypogammaglobulinaemic (serum IgG o5 gm/L) beyond this time. All patients not receiving routine IVIG beyond day 100 post HPCT were restarted on IVIG (0.4 mg/kg/day for 1-5 days) if suffering from RSV/PIV3 LRTI. RSV Ig was not available for use at our institution. Patients were continued on oral RBV until the resolution of URTI/LRTI symptoms and/or documentation of viral clearance by repeat NPA testing.
No stratification was performed with respect to patient selection and commencement of therapy with oral RBV; any post-HPCT patient, irrespective of follow-up, with symptoms of viral infection and positive NPA for RSV or PIV3 was commenced on oral RBV as per the protocol described above.
URTI was defined by the combination of upper respiratory symptoms (fever 438 1C, sinusitis, rhinorrhoea, sore throat þ / À cough) and positive NPA but absence of pulmonary infiltrates on radiology by chest X-ray or CT scan. LRTI was diagnosed when concomitant pulmonary infiltrates were present on chest radiology.
RESULTS
Overall, 15 patients had received oral RBV for either RSV (n ¼ 13) or PIV3 (n ¼ 2) infection. Patient demographics and transplant characteristics are shown in Table 1 . Most patients (67%) had received reduced intensity conditioning with fludarabine plus melphalan. All grafts were T-cell replete with standard GVHD prophylaxis cyclosporine plus MTX, or cyclosporine plus mycophenolate mofetil for recipients of fludarbine plus TBI conditioning. For patients infected with RSV, risk factors for progression to LRTI and overall mortality, as outlined in the recent European Conference on Infections in Leukaemia (ECIL) guidelines, 11 are shown in Table 2 .
At diagnosis of RSV/PIV3 infection, seven patients had URTI and eight had LRTI. The median time for commencement of RBV from symptom onset was 3 days (range 1-6 days) for those presenting with URTI and 6 days (range 2-14 days) for those presenting with LRTI (Table 1) .
Of the seven patients presenting with URTI, all suffered from RSV infection and all developed their infection early post HPCT, a median of 14 days (range 1-39 days) post progenitor cell infusion. For these seven patients, the commencement of oral RBV at 10 mg/kg/day did not appear to prevent progression to LRTI, with all seven patients subsequently developing pulmonary infiltrates after the initiation of RBV. However, with ongoing RBV dose escalation, RSV infection did appear to subsequently respond to RBV in six cases (86%), with resolution of symptoms þ / À clearance of virus on repeat NPA (see Table 1 ). The median final RBV dose received by these six patients was 35 mg/kg/day (range 10-55 mg/kg/day), and median duration of therapy was 25.5 days (range 10-33 days). One patient was unresponsive to dose escalation of RBV and subsequently died from RSV-related pneumonitis (palliated outside of intensive care).
For the eight patients initially presenting with LRTI, six (75%) harboured RSV and two (25%) PIV3. Median time to LRTI post progenitor cell infusion was also short at 14 days (range 2-730 days). Overall, six patients appeared to respond to RBV, with resolution of symptoms and radiology changes þ / À clearance of virus on repeat NPA (see Table 1 ); median final dose of RBV received by these six patients was 25 mg/kg/day (range 20-40 mg/ kg/day), and median duration of RBV therapy was 15 days (range 5-41 days). Two patients did not respond to RBV and subsequently died from respiratory failure; these were the only two patients who received mechanical ventilation in the entire cohort.
No patient ceased RBV treatment therapy owing to side effects or intolerance. In total, four patients (27%) experienced mildly deranged liver function tests (grade 1 elevation of transaminases); none suffered renal dysfunction or haemolysis. Of the 12 surviving patients, 3 (25%) were able to be discharged from the hospital while continuing RBV as outpatients until resolution of clinical symptoms/viral clearance occurred.
Concomitant corticosteroids (i.v. methylprednisolone in all cases) were used in seven patients (47%), including in one patient already receiving steroids for a drug eruption before diagnosis of RSV URTI and four patients commenced methylprednisolone after the development of RSV/PIV3 pneumonitis. All five of these patients eventually cleared their virus and survived their infection (Table 1) . A further two patients with RSV infection were commenced on methylprednisolone after developing complications consistent with diffuse alveolar haemorrhage; both of these patients subsequently died from RSV-associated respiratory failure. Overall, there was no significant difference in duration of RBV therapy between those patients treated with and those not treated with concomitant methylprednisolone, with a median duration of therapy of 25 days (range 8-41 days) versus 21 days (range 5-33 days), respectively (P ¼ 0.65).
DISCUSSION
Historically, the outcome of RSV and PIV3 infections occurring post HPCT is poor, with reported mortality rates ranging from 7 to 78% in published series. [1] [2] [3] [4] 8, 12, [14] [15] [16] [17] [18] [19] [20] [21] Furthermore, the development of LRTI has been consistently associated with significantly higher risk of death. 12, 13, 17, 18 Early intervention with antiviral therapy has been demonstrated to reduce the risk of progression to pneumonia 7 and may lead to improved survival. 22 The importance of commencing RBV early is highlighted by the lower response to RBV once PIV3 viral infection is well established. 3 In an HPCT setting, the use of RBV before engraftment has been shown to not affect time to white cell engraftment, 8 hence allaying concerns with respect to RBV use in this period. Against this background, our experience of 80% survival with only 13% RSV/PIV3-related mortality in a series of 15 patients in whom LRTI developed in all suggests that oral RBV does indeed have significant clinical efficacy in the treatment of RSV/PIV3 infection post HPCT.
All seven patients presenting with URTI subsequently developed signs and symptoms of LRTI despite commencement of oral RBV at 10 mg/kg/day. However, with subsequent dose escalation of RBV, six of the seven patients cleared their virus and five of the seven patients survived. This suggests that oral RBV at a dose of 10 mg/kg/day is too low for the treatment of RSV/PIV3, and that higher doses are required for efficacy. This is consistent with data from lung transplantation, where the starting dose of oral RBV is typically 15-33 mg/kg, 23-26 a dose not dissimilar to the median final RBV dose in our patient cohort.
Unlike recent recommendations from the ECIL, 11 an initial loading dose of RBV was not incorporated into our oral RBV protocol. However, our treatment protocol was introduced several years before the recently published ECIL guidelines. Of note, even within these guidelines, dose recommendations for oral RBV were based upon data from one retrospective single-centre study incorporating palivizumab in the treatment schedule. 17 Given the overall limited literature available on efficacy of oral RBV in a post-HPCT setting, 8, 12, 17, 22, 27 we believe that exploring different RBV dosing schedules is reasonable.
The maximum RBV dose of 60 mg/kg/day used in our protocol was based on previously published data suggesting good tolerability of oral RBV up to these dosing levels. 27 Our experience was similar to this prior publication, with oral RBV at doses of up to 55 mg/kg/day exceedingly well tolerated, with no significant and/or dose-limiting toxicity observed.
The duration of oral RBV therapy required to best treat RSV/PIV3 infection in post-HPCT patients is not clear. Prior publications have continued oral RBV until virological clearance was achieved, as assessed by either PCR or direct immunofluorescence on respiratory secretions. 8, 17, 27 We used a similar end point for cessation of oral RBV in our protocol. However, the use of this stopping definition clearly required prolonged duration of RBV therapy (median 25 days, range 5-41). Although oral RBV may allow the ability to potentially discharge patients to continue their antiviral therapy in an ambulatory care setting, the prolonged duration of therapy required to achieve virological clearance also raises the question as to whether or not therapy could be safely ceased earlier, at clinical symptom resolution. As we are unaware of any clinical studies in a post-HPCT setting adequately addressing this question, we still suggest the use of virological clearance as the stopping point for RBV therapy.
Corticosteroids have also been demonstrated to increase viral shedding, 28 and the use of methylprednisolone in our cohort may have potentially contributed to the overall prolonged duration of oral RBV required to achieve virological clearance. Although it is noteworthy that the individual who took the longest time to Oral RBV post HPCT J Casey et al achieve negative NPA results was also treated with concomitant steroids, overall we saw no significant difference in the duration of RBV therapy between those patients treated with and those not treated with concomitant methylprednisolone (Table 1) . Further research on the clinical impact of concomitant corticosteroids in RSV/PIV3 infection in HPCT populations is needed. There are clearly several limitations to our findings, notwithstanding small patient numbers and the retrospective analysis of results. We also cannot comment on the overall incidence of RSV/ PIV3 infection within our post-transplant population, as we did not measure how many patients with symptoms suggestive of viral respiratory infection actually did versus did not undergo an NPA. However, our experience does suggest that oral RBV has significant clinical efficacy in the therapy of RSV/PIV3 infection post HPCT. Overall, the drug is well tolerated and easy to manage, including in an ambulatory care setting. Our findings suggest that a starting dose of 410 mg/kg/day appears necessary for clinical efficacy. On the basis of our experience, we suggest a starting dose of at least 20 mg/kg/day, with dose escalation to a maximum of 60 mg/kg/day as clinically required. Confirmation of these results in a larger cohort of patients is required. Oral RBV post HPCT J Casey et al
